New injection aims to tame stubborn autoimmune conditions
NCT ID NCT07333118
First seen Jan 12, 2026 · Last updated May 16, 2026 · Updated 22 times
Summary
This early-stage trial tests a new treatment called GT801 for people with moderate-to-severe autoimmune diseases that haven't improved with standard therapies. The study will enroll 22 participants to check safety and how well the treatment works. Researchers will monitor side effects and measure disease activity in conditions like lupus and inflammatory myopathies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE REFRACTORY AUTOIMMUNE DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Changzheng Hospital
RECRUITINGShanghai, Shanghai Municipality, 200003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.